Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.11 USD | +2.75% | +3.00% | -83.42% |
14/05 | Wolfe Research Downgrades RAPT Therapeutics to Peer Perform From Outperform | MT |
10/05 | Guggenheim Downgrades RAPT Therapeutics to Neutral From Buy | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-83.42% | 14Cr | |
+8.27% | 12TCr | |
+12.81% | 11TCr | |
-13.48% | 2.23TCr | |
-4.22% | 2.16TCr | |
-6.00% | 1.82TCr | |
-39.93% | 1.76TCr | |
+7.33% | 1.43TCr | |
+33.51% | 1.24TCr | |
-27.25% | 828.11Cr |
- Stock Market
- Equities
- RAPT Stock
- News RAPT Therapeutics, Inc.
- RAPT Therapeutics Starts Mid-Stage Trial in Moderate-to-Severe Asthma